Drugs that contain Pegaptanib Sodium
1. Macugen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6113906 | BAUSCH AND LOMB INC | Water-soluble non-antigenic polymer linkable to biologically active material |
Oct, 2013
(10 years ago) | |
| US5919455 | BAUSCH AND LOMB INC | Non-antigenic branched polymer conjugates |
Oct, 2013
(10 years ago) | |
| US6051698 | BAUSCH AND LOMB INC | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
May, 2015
(8 years ago) | |
| US5932462 | BAUSCH AND LOMB INC | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
Aug, 2016
(7 years ago) | |
| US6011020 | BAUSCH AND LOMB INC | Nucleic acid ligand complexes |
Jan, 2017
(7 years ago) | |
Market Authorisation Date: 17 December, 2004
Treatment: Treatment of vegf mediated ocular disease.
Dosage: INJECTABLE;INTRAVITREAL
More Information on Dosage
MACUGEN family patents
